Utah medical cannabis sales reached $16.4 million in June, bringing the state’s total for the first half of 2026 to $100.4 million, according to the newest monthly report from the Utah Department of Health and Human Services.
The June total, $16,442,800, was based on product-category sales listed in the state’s report. The figure includes $8,021,300 in cartridges and pens, $5,476,300 in flower, $2,724,900 in infused edibles, $104,200 in infused non-edible products and $116,100 in non-medicated products.
The new year-to-date total was calculated by adding June’s sales to the roughly $84 million in medical cannabis sales reported during the first five months of the year.
The report shows Utah had 115,472 patients with active medical cannabis cards as of data retrieved July 1. That is up 1,382 from the 114,090 active patients listed in the May report, continuing steady growth in the state’s medical cannabis program.
Among active patients, the largest age group was 31 to 40, with 30,180 patients, followed by those ages 41 to 50 at 25,820 and those ages 21 to 30 at 25,265. Patients 65 and older accounted for 12,872 cardholders.
Persistent pain remained by far the most common qualifying condition, with more than 100,000 patients listed under that category. PTSD was the second-highest condition at 5,490 patients, followed by nausea at 2,465 and cancer at 2,118.
The report also shows 63,491 patients made at least one purchase in the previous 30 days, while 36,238 made two or more purchases and 22,111 made at least three. Over the previous 90 days, 89,044 patients made at least one purchase.
Utah’s program also included 1,028 registered recommending medical providers, 161 paper-only recommending providers, 965 pharmacy agents, 950 processor or cultivator agents and 445 courier agents.
Utah legalized medical cannabis in 2018, with the state’s first medical cannabis pharmacy opening in March 2020. The program does not allow recreational marijuana sales.
